The British Labour Party’s platform on access to health, “MEDICINES FOR THE MANY: Public Health before Private Profit,” is organized in five well-written and powerful policy chapters. In 52 pages, the Labour Party takes a strong stand defending patients instead of profits. It also provides a clear explanation of a new set of needed health policies, fully laying out rationale to implementation. The first chapter covers the current United Kingdom (UK) health system including the pricing of medicines. The second chapter deals with the many problems that plague the existing health care system from the lack of transparency to the pharmaceutical lobby. The third chapter,Read More →

The following are comments by the Union for Affordable Cancer Treatment (UACT) on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to the notice published in the Federal Register, 83 FR 22692. Element II.B. of the notice asks, “What policies should the U.S. government pursue in order to protect IP rights and address concerns around compulsory licensing” in OECD countries, which “are not paying an appropriate share of the necessary research and development to bring innovative drugs to the market and are instead freeriding off U.S. consumers and taxpayers.” 1. UACT rejects the premise put forth by the Blueprint thatRead More →